Genmab shares are trading higher after the company and AbbVie reported Phase 3 EPCORE DLBCL-2 results showing epcoritamab plus R-CHOP improved progression-free survival and reduced the risk of disease progression or death by 51% versus R-CHOP alone.

Genmab Reports Q3 DARZALEX Net Sales Of $4.239B

Worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J

Truist Securities Maintains Buy on Genmab, Raises Price Target to $45

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $45.

Guggenheim Maintains Buy on Genmab, Raises Price Target to $58

HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $50

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $50.